Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2002 1
2005 1
2009 2
2010 1
2011 1
2012 1
2013 2
2014 1
2015 1
2016 4
2017 3
2018 4
2019 4
2020 8
2021 6
2022 4
2023 1
2024 4
2025 7
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Democratized single-cell proteomics resolves cell state heterogeneity in skin tumors.
Inns J, Frey AM, Ng WW, Trost M, Rajan N. Inns J, et al. Life Sci Alliance. 2026 Jun 29;9(9):e202603759. doi: 10.26508/lsa.202603759. Print 2026 Sep. Life Sci Alliance. 2026. PMID: 42373542 Free PMC article.
We tested this methodology in a skin tumor syndrome, CYLD cutaneous syndrome (CCS), assessing tumor heterogeneity. Using a Bruker timsTOF HT platform, we quantified >4,000 proteins, averaging 700 per cell, through a cost-effective pipeline without …
We tested this methodology in a skin tumor syndrome, CYLD cutaneous syndrome (CCS), assessing tumor heterogeneit …
The importance of challenging dogma with patient data.
Ádám É, Hajdu A, Hodgson K, Danis J, Nagy N, Rajan N, Széll M. Ádám É, et al. J Invest Dermatol. 2026 Jun 15:S0022-202X(26)02598-4. doi: 10.1016/j.jid.2026.05.025. Online ahead of print. J Invest Dermatol. 2026. PMID: 42297131 Free article. No abstract available.
Case Report: CYLD cutaneous syndrome with malignant transformation to spiradenocarcinoma: cooperative effects of CYLD truncation and an MSH2 clamp-domain variant in an Ecuadorian patient.
Reyes-Silva C, Jaramillo-Koupermann G, Quishpe M, Pacheco R, Burgos-Tapia S, Zambrano AK, Cabrera-Andrade A. Reyes-Silva C, et al. Front Med (Lausanne). 2026 Feb 18;13:1703885. doi: 10.3389/fmed.2026.1703885. eCollection 2026. Front Med (Lausanne). 2026. PMID: 41788709 Free PMC article.
BACKGROUND: CYLD cutaneous syndrome (CCS) is a rare autosomal dominant disorder caused by germline CYLD variants and characterized by multiple skin adnexal tumors. ...Whole-exome sequencing identified a heterozygous nonsense CYLD variant (c.1207 …
BACKGROUND: CYLD cutaneous syndrome (CCS) is a rare autosomal dominant disorder caused by germline CYLD variants …
Targeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IkappaB kinase alpha.
Hodgson K, Inns J, Reynolds G, Stephenson E, Paul A, Sinclair N, Berretta G, Lawson C, Frey AM, Ivanova I, Adam E, Lord CJ, Cockell S, Coxhead J, Nagy N, Adams D, Szell M, Trost M, Haniffa M, Mackay SP, Perkins N, Rajan N. Hodgson K, et al. Br J Dermatol. 2026 May 19;194(6):1130-1141. doi: 10.1093/bjd/ljag044. Br J Dermatol. 2026. PMID: 41779628 Free PMC article.
BACKGROUND: CYLD cutaneous syndrome (CCS) skin tumours develop from puberty onwards, can number in the hundreds and progressively grow over time. ...CONCLUSIONS: These data provide the preclinical rationale for the assessment of topical IKKalpha inhibitors as …
BACKGROUND: CYLD cutaneous syndrome (CCS) skin tumours develop from puberty onwards, can number in the hundreds and pro …
Multiple Skin Adnexal Tumours with Possible Syndromic Association.
Sridhar J, Balasubramanian A, Joseph L, Fernandez D, B A R. Sridhar J, et al. Cureus. 2026 Jan 26;18(1):e102352. doi: 10.7759/cureus.102352. eCollection 2026 Jan. Cureus. 2026. PMID: 41769434 Free PMC article.
As allelic conditions caused by mutations in the CYLD gene, they are considered variants of a spectrum termed CYLD cutaneous syndrome (CCS). ...The patient underwent excision of the lesions with skin grafts and, given the possibility of syndromic …
As allelic conditions caused by mutations in the CYLD gene, they are considered variants of a spectrum termed CYLD cutaneou …
CYLD Cutaneous Syndrome and Associated Salivary Gland Pathology: A Systematic Review.
Tong JY, Bzhilyanskaya V, Ludeman E, Wen C, Hatten K. Tong JY, et al. OTO Open. 2026 Feb 6;10(1):e70199. doi: 10.1002/oto2.70199. eCollection 2026 Jan-Mar. OTO Open. 2026. PMID: 41658315 Free PMC article. Review.
OBJECTIVE: To characterize salivary gland pathology and neoplasms associated with CYLD cutaneous syndrome, including location, risk of malignancy, and management practices. ...REVIEW METHODS: Following Preferred Reporting Items for Systematic Review and Meta- …
OBJECTIVE: To characterize salivary gland pathology and neoplasms associated with CYLD cutaneous syndrome, including lo …
Advanced CYLD Cutaneous Syndrome (CCS) Treated With the Hedgehog Signaling Pathway Inhibitor Vismodegib Results in a Limited Clinical Response.
Kaae J, Gjerdrum LMR, Poulsen TS, Hoegdall E, Jemec GB. Kaae J, et al. APMIS. 2025 Dec;133(12):e70104. doi: 10.1111/apm.70104. APMIS. 2025. PMID: 41321185
CYLD Cutaneous syndrome (CCS) is a rare autosomal dominantly inherited disease associated with multiple nodular adnexal skin tumors, most commonly trichoepitheliomas and cylindromas. ...A patient treated with the Hedgehog Pathway Inhibitor Vismodegib. The …
CYLD Cutaneous syndrome (CCS) is a rare autosomal dominantly inherited disease associated with multiple nodular adnexal …
59 results